TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drugs
Research reports on drugs from Postgraduate Institute of Medical Education and Research provide new insights
March 25th, 2008
Researchers detail in 'Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles,' new data in drugs. According to a study from Chandigarh, India, "The potential of econazole (ECZ) and moxifloxacin (MOX) individually against tuberculosis (TB) caused by multidrug-resistant and latent Mycobacterium tuberculosis has been demonstrated. In this study, poly-(dl-lactide-co-glycolide) (PLG) nanoparticle-encapsulated ECZ and MOX were evaluated against murine TB (drug susceptible) in order to develop a more potent regimen for TB." "PLG nanoparticles were prepared by the multiple emulsion and solvent evaporation...
Source: TB & Outbreaks Week (2008-03-25)
|
